Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Amyris, Inc.

We are investigating Amyris, Inc. (AMRS) (“Amyris” or the “Company”) for potential violations of the federal securities laws. 

On November 13, 2018, Amyris reported disappointing financial results for the third quarter of 2018, including revenue of $14.9 million compared to $22.5 million in the prior year period, citing the “volatility of the Vitamin E market.”  On this news, Amyris’s stock price fell $1.76 per share, or 29.83%, to close at $4.14 per share on November 14, 2018.  Then, on March 19, 2019, Amyris disclosed that it would be unable to timely file its annual report due to “significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018.”  Amyris also disclosed that it “is in the process of completing its evaluation of internal control over financial reporting and may have further deficiencies to report.”  On this news, Amyris’s stock price fell $0.78 per share, or 20.10%, to close at $3.10 per share on March 20, 2019.